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Dominique Slaets* and Filip De VosAbstract
Background: Until now, no kinetic model was described for the oncologic tracer [18F]fluoromethylcholine ([18F]
FCho), so it was aimed to validate a proper model, which is easy to implement and allows tracer quantification in
tissues.
Methods: Based on the metabolic profile, two types of compartmental models were evaluated. One is a 3C2i
model, which contains three tissue compartments and two input functions and corrects for possible [18F]
fluorobetaine ([18F]FBet) uptake by the tissues. On the other hand, a two-tissue-compartment model (2C1i) was
evaluated. Moreover, a comparison, based on intra-observer variability, was made between kinetic modelling and
graphical analysis.
Results: Determination of the [18F]FCho-to-[18F]FBet uptake ratios in tissues and evaluation of the fitting of both
kinetic models indicated that corrections for [18F]FBet uptake are not mandatory. In addition, [18F]FCho uptake is
well described by the 2C1i model and by graphical analysis by means of the Patlak plot.
Conclusions: The Patlak plot is a reliable, precise, and robust method to quantify [18F]FCho uptake independent of
scan time or plasma clearance. In addition, it is easily implemented, even under non-equilibrium conditions and
without creating additional errors.
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[18F]Fluoromethylcholine ([18F]FCho) and [11C]choline
([11C]Cho) are radiolabelled biomarkers to study the
altered phospholipid metabolism in tumours. Several
ongoing clinical trials evaluate their use as diagnostic [1]
or as therapy response assessment [2,3] tools. The latter
requires quantification of the tracer uptake. Thus far,
this is executed in a semi-quantitative way using stan-
dardized uptake values (SUV) [4], the percent of injected
dose per gram of tissue (%ID/g) [3], or by comparing
tumour-to-muscle ratios [5]. SUV have an advantage in
that they are straightforward to estimate, but when
applied in a clinical setting, care should be given about
standardization [6]. On the other hand, absolute quanti-
fication of tracer uptake, by means of kinetic modelling,* Correspondence: dominique.slaets@ugent.be
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reproduction in any medium, provided the origis more complex since it requires dynamic scanning and
arterial sampling. Nevertheless, this technique is more
reliable and independent of scan time or plasma clear-
ance, allowing a more accurate quantification of the
tracer uptake [7].
Until now, no kinetic model was described for [18F]
FCho, so it was aimed to validate a proper model, which is
easy to implement and allows quantification of [18F]FCho
uptake in tissues. The validation studies were performed
on laboratory animals, i.e. mice, since no (fundamental)
differences in choline metabolism between mice and hu-
man tissues were reported. Moreover, both species are
characterized by a fast and explicit oxidative metabolism
of [18F]FCho into the osmolyte [18F]fluorobetaine ([18F]
FBet). Therefore, a test was performed to evaluate if this
metabolite is characterized by a specific uptake in the
tissues, eventually provoking overestimation of the [18F]
FCho uptake in tissues. To verify this possibility, two typesis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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3C2i model which contains three tissue compartments
and two input functions (one for [18F]FCho and one for
[18F]FBet) and corrects for possible [18F]FBet uptake by
the tissues, and a 2C1i model which contains two tissue
compartments and one input function and quantifies the
[18F]FCho uptake, based exclusively on [18F]FCho plasma
concentrations. As kinetic modelling, using non-linear
least squares optimisation, is computationally expensive
and sensitive to noise, a comparison will be made between
kinetic modelling and graphical analysis to quantify [18F]
FCho uptake in tissues. The latter uses a linearization of
the compartmental equations, resulting in a faster method
which is less sensitive to noise [7].
Methods
Athymic Swiss Nu/Nu mice (female, 20 g) were obtained
from Charles River Laboratories International (Janvier,
France). Sulphuric acid, urea, dimethylaminoethanol,
chloroform, and methanol were purchased from Sigma-
Aldrich (Steinheim, Germany). Physiological saline was
obtained from B.Braun Medical Ltd. (Sheffield, UK).
Isoflurane and heparin were obtained from Medini N.V.
(Oostkamp, Belgium).
Radiochemistry
[18F]FCho was prepared by nucleophilic substitution of
dimethylaminoethanol to [18F]fluoromethylbromide as
described by Slaets et al. [8].Figure 1 Visual representation of the different kinetic models.
(a) Schematic of a two-tissue-compartment model with one input
function (2C1i). Transfer coefficients K1 and k2 describe the uptake
and washout of the free tracer and its metabolite ([18F]FBet) across
cell membranes. Rate constant k3 is regarded as the conversion of
[18F]FCho into [18F]FPCho, which is assumed to be metabolically
trapped in the cell. Micro-parameter k4 represents dephosphorylation and
is expected to be very small. (b) Schematic of a three-tissue-compartment
model with two input functions (3C2i). Rate constants K1p and K1m,
or k2p and k2m represent respectively the uptake and washout of
[18F]FCho and [18F]FBet.Positron emission tomography
All animal experiments were approved by the local eth-
ics committee (ECD 11/30). Mice (n = 6) were harvested
8 h prior to the study and anaesthetized with isoflurane
(1.5% + 1.5 L/min O2) during cannulation, animal hand-
ling, and acquisition time. Prior to positioning on the
heated scanner bed, the mice were venously and arteri-
ally cannulated for tracer injection and arterial blood
sampling, respectively. Positron emission tomography
(PET) was performed using a Flex Triumph II μPet scan
(Gamma Medica, Sherbrooke, Quebec, Canada) with a
7.5-cm axial field of view and a 1.2-mm spatial reso-
lution. After the synchronized start of the arterial blood
sampling and the start of the μPET acquisition, the
tracer was intravenously injected (±11.1 MBq in 150 μL
saline) over a constant infusion interval of 5 s. List mode
data were acquired for 40 min.
Arterial input function determination
Blood concentration
Continuous arterial blood samples were withdrawn for
40 min at a rate of 10 μL/min using a microvolumetric
blood counter (μBC, Gamma Medica-Ideas) as described
by Convert et al. [9]. Heretofore, a 60-cm PE10 catheter
filled with heparinized saline (50 U/mL) was inserted in
the carotid artery and the withdrawing syringe was
placed at the end. At a distance of 20 cm from the
mouse, the catheter was placed in the calibrated detector
unit of the μBC. The obtained blood curve (g(t)) was
automatically corrected for decay and propagation delay.
Corrections for dispersion were performed using
Equation 1:
Cbl tð Þ ¼ g tð Þ þ τdisp  dgdt : ð1Þ
In Equation 1, g(t) depicts the original blood curve, dgdt
describes the first derivative of the original blood curve,
τdisp is a constant calculated as described by [9], and Cbl
represents the for dispersion-corrected blood curve.
Plasma concentration and metabolites
The ratio of the tracer plasma to blood concentration
and metabolite profile was determined ex vivo in Swiss
NuNu mice (n = 4 per time point) by an intravenous
injection of 22.2 MBq [18F]FCho in 150 μL saline. Blood
(200 μL) obtained by cardiac puncture in the left heart
ventricle at 0.5, 2.5, 10, 20, and 40 min post injection
was collected in heparinized tubes and spiked with 5%
sulphuric acid (100 μL) and a 40% urea solution
(100 μL) before centrifugation (5 min, 3,000×g). Plasma
and the hematocrit pellet were separated and assessed
for radioactivity. Then, 600 μL of the Bligh and Dyer ex-
traction solution containing CHCl3:MeOH:H2O (1:2:1)
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except that of 0.5 min (post injection) p.i. and mixed
vigorously before centrifugation (5 min, 3,000×g).
Finally, the two layers were separated and assessed for
radioactivity, and 500 μL of the aqueous layer was
injected to a semi-preparative high-performance liquid
chromatography (HPLC) system for aqueous metabolite
analysis as described by Bansal et al. [10]. The HPLC
system consisted of a Waters 1525 binary pump (Waters,
Milford, MA, USA), a Waters Breeze data acquisition, and
an Alltima silica NP column (5 μm, 10 × 250 mm).
The following gradient elution [10] was used at a rate
of 7 mL/min. The retention time of [18F]FCho was
determined by extraction (vide supra) of the reference
solution and was 14.4 min. The metabolite [18F]FBet
had a retention time of 12.4 min in the chromato-
graphic separation. During separation, fractions of
20 s were collected and assessed for radioactivity. The
tracer plasma-to-blood concentration ratio was calcu-





% pl i:e: 0:60ð Þ

CPSbl
% bl i:e: 1:00ð Þ
ð2Þ
In Equation 2, the ratio of the plasma to blood
concentration is calculated for several time points (vide
supra). The plasma concentration (Cpl) was determined
by dividing the counts in the plasma (CPSpl) to the
standardized volume of plasma in blood (%pl, which is
expressed as 0.6). In analogy, the tracer blood con-
centration (Cbl) was calculated by taking the ratio of the
sum of the counts in the plasma and hematocrit pellet
(represented by CPSbl) to the blood volume, which is
expressed as 1.
The obtained ratios and metabolite percentages were
fitted to a single-phase exponential curve. The goodness
of the fit and the equation were calculated using
GraphPad Prism 5.00 for Windows (San Diego, CA,
USA; www.graphpad.com).
Image reconstruction and corrections
Dynamic images were reconstructed using the MLEM
2D algorithm with ten iterations to the following time
frames: 12 s × 5 s, 6 s × 10 s, 6 s × 20 s, 6 s × 60 s, 4 s ×
120 s, 3 s × 300 s, and 1 s × 360 s. Quantification of the
PET scan was performed relative to a 22Na source placed
on the base of the scanning bed.
Regional time-activity curve computation
The last time frame was used to draw a region of inter-
est on two to three adjacent slices on a part of the tissue
of interest, namely the brain, kidney, lung, liver, and
muscle. The ROIs were then placed over the completeseries of time frames to derive tissue time-activity
curves.
Kinetic modelling
The exploit of kinetic modelling to [18F]FCho is based
on the following general assumptions [11,12]:
There is a single source for [18F]FCho, i.e. the plasma.
The concentration varies with time, and transfer from
the plasma to the first tissue compartment is reversible.
The capillary concentration of [18F]FCho is assumed to
be equal to the arterial plasma concentration, so no
gradient could be observed across the capillary
membranes.
Since tracer amounts were injected (high specific
activity), the test solute did not alter the system and
first-order kinetics could be assumed.
[18F]FCho is homogeneously distributed in the tissues.
Metabolism of choline is under steady state, so the
concentration of phosphocholine stays constant during
imaging.
In addition to the previous assumptions, [18F]FCho is
metabolized to (1) [18F]fluorophosphocholine which is
suspected to be metabolically trapped and (2) [18F]FBet,
an osmolyte, which is able to cross the cell membranes.
Kinetic analysis was performed using a 3C2i as de-
scribed by Fujita et al. [13] and was weighed against a
2C1i (Figure 1). The models are described by following
the micro-parameters: K1, k2, k3, and k4 for the 2C1i
model; and the additional parameter K1p/K1m which
represents the ratio of [18F]FCho to [18F]FBet uptake in
tissues in the 3C2i model. Transfer coefficients K1 and
k2 describe the uptake and washout of the free tracer
and its metabolite ([18F]FBet) across cell membranes.
Rate constant k3 is regarded as the conversion of [
18F]
FCho into [18F]FPCho, which is assumed to be metabo-
lically trapped in the cell. Micro-parameter k4 represents
dephosphorylation and is expected to be very small. The
3C2i model differentiates between [18F]FCho and [18F]
FBet uptake or washout by rate constants K1p and K1m,
or k2p and k2m, respectively. During the fitting process
using the 3C2i model, six parameters were identified.
The vascular volume parameter, present in both models,
was not accounted for due to the fast clearance of [18F]
FCho. Parameters of interest were the ratio of [18F]FCho
to [18F]FBet uptake in tissues, represented by K1p/K1m
for the 3C2i model, and the [18F]FCho influx across the
membranes (Ki) calculated as K1*k3/(k2 + k3) [14-16] for
both models.
Before the selected kinetic models were fitted, the
tracer plasma curves were fitted using a three-
exponential decay function [17]. Then, model fitting was
conducted and optimized by (1) visual inspection of the
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output, (2) evaluation of the percent coefficient of vari-
ation of the micro-parameters, and (3) the goodness of
fit displayed by the Akaike information criterion (AIC),
Schwartz criterion (SC), and model selection criterion
(MSC) as determined by the PMOD software (PMOD
version 3.0; PMOD group, Zurich, Switzerland). When
the fitting was poor, fits were redone by adjusting the
initial parameters. Parameter estimation, in kinetic
modelling, was performed using the Marquardt-
Levenberg algorithm, which uses a non-linear least
squares optimization process, included in the PMOD
software.
Graphical analysis
Since absolute quantification of [11C]Cho was already
established by means of the Patlak plot [12,17], this
graphical analysis was also applied for [18F]FCho. The
macro-parameter of interest, i.e. the slope, which resem-
bles [18F]FCho influx into the cells, was determined
under non-equilibrium and equilibrium conditions. The
latter is usually achieved when the graphical plot
describing normalized tissue concentration as a function
of the normalized time becomes linear [11,12]. It is
worth noting that the Patlak slope corresponds to the
macro-parameter of interest Ki, defined previously dur-
ing the kinetic modelling process.
Intra-observer variability of macro-parameters
A test was performed to evaluate the robustness of
the macro-parameter estimation of the [18F]FCho in-
flux (i.e. Ki) (vide supra) using these three models, i.e.
3C2i, 2C1i, and the Patlak plot. The percent error is
calculated as (Cho influx test − Cho influx retest/
(mean test and retest).
Statistical analysis
Statistical analysis was performed using Graphpad Prism
5.00. A D'Agostino-Pearson test was conducted to test
for normality distribution of the data. Since samplesFigure 2 Determination of the arterial input function. (a) A time-activit
dispersion-corrected whole blood curve (black squares). (b) The single-pha
concentration. Data points are expressed as mean ± S.D. (c) The single-pha
a function of time after injection. Data points are expressed as mean ± S.Dwere too little, non-parametric statistical tests were used.
A Bland-Altman plot was determined to evaluate the
percent error during the intra-observer variability test. A
Kruskal-Wallis test was performed to evaluate statistical
differences between (1) the AIC, SC, and MSC fitting
factors of the different models evaluated and (2) the
determined [18F]FCho influxes across the cell membrane
by comparing the macro-parameter Ki. A Wilcoxon
signed-rank test was applied to evaluate if the median
ratio K1p/K1m, which represents the ratio of [
18F]FCho
to [18F]FBet uptake in tissues in the 3C2i model, was
statistically different from 1. A Spearman correlation test
was performed to evaluate the influence of equilibrium
conditions on the model's Patlak slope. Differences were
regarded as statistically significant for p < 0.05.
Results
Arterial input function determination
Since kinetic modelling requires an arterial plasma in-
put function of the unmetabolized tracer, corrections
are forced on the blood curve which was obtained by
the microvolumetric blood counter. The corrections
applied were dispersion correction, conversion of the
blood curve into a plasma curve, and corrections for
metabolites.
Dispersion
Based on the specification of tubing diameter (PE 10),
withdrawal speed (10 μL/min), and distance to the
detector unit (i.e. 20 cm), the τdisp constant was calcu-
lated as 12.2092 s. All blood curves were first smoothed
by calculating the average concentrations (kBq/cm3) in
agreement with the μPET mid-time frames and then
corrected for dispersion as described by Equation 1. An
original blood curve and its corresponding dispersion-
corrected blood curve are displayed in Figure 2a.
Plasma concentration
The ratio of the plasma to blood concentration was
fitted by a single-phase exponential decay (Figure 2b) withy curve determined by the blood counter (grey circles) and for the
se exponential decay fitting of the ratio of the tracer plasma to blood
se exponential fitting of the percentages of [18F]FCho and [18F]FBet as
.
Slaets and De Vos EJNMMI Research 2013, 3:66 Page 5 of 9




¼ 0:6007  e−0:4559time minð Þ þ 1:116: ð3Þ
The plasma concentration was achieved by multiplying
the obtained ratios for each time point by the dispersion-
corrected blood curve as determined previously.
Corrections for metabolites and parent compound
Use of the Bligh and Dyer extraction mixture allowed
estimation of the percentage of lipophilic metabolites,
while the HPLC analysis of the hydrophilic fraction
allowed identification and quantification of the amount of
hydrophilic metabolites and parent compound in the
plasma. The fraction of lipophilic compounds in the
plasma was lower than 5% for all time points (Table 1);
therefore, no further corrections were made to correct for
the share of these metabolites. On the other hand, only
one hydrophilic metabolite, i.e. [18F]FBet, which appeared
rather quickly, was identified in the plasma (Figure 2c).
Indeed, after 10 min [18F]FBet already amounts to 58.54%.
The measured percentages of [18F]FCho and [18F]FBet
were fitted to a single-phase exponential curve respect-
ively with Equations 4 and 5 and R2 = 0.9435.
% 18F
 




FBet ¼ 0:8043  e−0:1498 time minð Þ þ 0:7653
ð5Þ
The corresponding percentages per time point
obtained from Equations 4 and 5 were multiplied by the
plasma curves (vide supra) to obtain the input functions
for the selected compartmental models, i.e. the 2C1i and
3C2i models. The [18F]FCho plasma concentration was
the only input function in the 2C1i model, whereas the
[18F]FCho plasma concentration and the [18F]FBet
plasma concentrations were both used in the 3C2i
model.
Kinetic modelling
Prior to the mathematical modelling, the obtained input
function was fitted to a three-exponential function.Table 1 Percentage of lipophilic and hydrophilic [18F]
FCho metabolites present in arterial plasma




2.5 99.60 ± 0.13 0.40 ± 0.13
10 98.64 ± 0.05 1.36 ± 0.50
20 99.31 ± 0.07 0.69 ± 0.07
40 97.09 ± 1.21 2.91 ± 1.21When the 3C2i and 2C1i models were fitted to the
TACs, the goodness of fit was described by AIC, SC, and
MSC parameters presented in Table 2. Comparing these
parameters, no statistical differences were observed
between the 3C2i and the 2C1i model (p values for the
Kruskal-Wallis test were 0.9925, 0.8276, and 0.9342,
respectively), albeit reducing the number of compart-
ments accordingly decreased the percent coefficient of
variance (%COV) on the micro-parameter estimates
(data not shown).
For each tissue, the mean ratio of [18F]FCho to [18F]
FBet uptake in tissues (K1p/K1m) was larger than 1
(Figure 3). However, only the ratio of the muscle tissue
was statistically different from 1 (Wilcoxon signed-rank
test, p = 0.0313). Kidney tissue displayed the lowest
ratio, indicating an elevated (or slightly higher) [18F]FBet
uptake compared to the other tissues. It is worth
noting that ratios with a %COV higher than 250% were
treated as unreliable and were excluded from the
dataset. When comparing the estimates of the [18F]FCho
influxes across the cell membrane by Ki determination
with or without corrections for possible [18F]FBet uptake
(3C2i versus 2C1i model), no significant differences
were observed for both models (Kruskal-Wallis test,
p value = 0.8670) (Figure 4).
Graphical analysis
Equilibrium conditions of the tracer were determined
and were usually achieved between 1 and 23 min after
injection. Then, linear regression was applied to the data
with a good fit (Chi square, 0.0054505 ± 0.0049021)
allowing estimation of the slope, which resembles the
[18F]FCho influx into the cell. When comparing the Cho
influxes Ki calculated for the 2C1i and 3C2i model with
the slope of the Patlak plot, a good agreement was
achieved and no statistical differences were observed
(Kruskal-Wallis test, p = 0.8270) (Figure 4).
Intra-observer variability of macro-parameters
To evaluate the robustness of the fitting of previously
described models, the intra-observer variability was de-
termined and depicted in a Bland-Altman plot (Figure 5).
This plot corroborates that reduction of the number of
compartments drastically reduces the percent error on
the intra-observer variability. Consequently, the lowest
intra-observer variability was obtained when graphical
analysis, by means of the Patlak plot, was applied. It
must be noted that the Patlak plot gave 0% error in
several cases, while the other models (3C2i and 2C1i)
almost never did.
Since a robust fitting was obtained for the Patlak plot,
it was investigated whether the tracer influx, determined
by the slope of the linear regression, varied under equi-
librium and non-equilibrium conditions. Several fittings
Table 2 Fitting factors per tissue (AIC, SC, and MSC) for 3C2i and 2C1i models
AIC SC MSC
3C2i 2C1i 3C2i 2C1i 3C2i 2C1i
Brain 90.54 ± 31.56 91.44 ± 21.48 98.72 ± 31.63 97.00 ± 21.68 1.36 ± 0.52 1.341 ± 0.425
Kidney 24.63 ± 34.18 19.40 ± 30.54 32.81 ± 34.23 25.19 ± 30.58 3.188 ± 0.634 3.292 ± 0.554
Liver 51.97 ± 50.19 61.03 ± 41.54 60.13 ± 50.16 66.68 ± 41.43 2.708 ± 1.308 2.544 ± 1.099
Lung 44.92 ± 24.72 47.79 ± 19.50 53.11 ± 24.75 49.06 ± 27.39 2.669 ± 0.616 2.600 ± 0.490
Muscle 92.96 ± 15.28 90.34 ± 15.73 100.5 ± 15.85 95.90 ± 15.93 1.489 ± 0.431 1.549 ± 0.333
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non-equilibrium conditions for all tissues, except the
kidneys (Figure 6), thereby proving the insensitivity of
the slope fitting in relation to the manual selection of
the data points. Indeed, equilibrium conditions were se-
lected by visual inspection and by including or excluding
data time points to obtain a linear fit. Non-equilibrium
conditions were obtained by including all data points in
the linear regression (Figure 7).
Discussion
Kinetic modelling requires arterial sampling which can
be obtained by taking continuous or discrete blood
samples. The latter is laborious, requires more animals
due to the limited blood volume, and is characterized by
complicated sampling intervals within a specific time
window. Therefore, we chose to use the validated
microvolumetric blood counter [9] to obtain continuous
arterial blood samples by cannulation of the carotid
artery by a precision operation and a syringe pump. The
obtained blood curve was first smoothed in order to
derive the first derivative, and then the dispersion
constant was applied for dispersion correction, which
occurred in the tubing during blood sampling.Figure 3 Visual representation of the [18F]FCho-to-[18F]FBet
uptake ratio in several tissues. The [18F]FCho-to-[18F]FBet uptake
ratio represented by K1p/K1m was determined by the 3C2i model.
The individual data points are shown, and the whiskers represent
mean and S.D. The dotted line represents a ratio equal to 1.Since only unbound tracer in plasma undergoes tissue
uptake, a ratio of the plasma to blood concentration
(Cpl/Cbl) was determined to convert the blood curve into
a plasma curve. Therefore, standard hematocrit ranges
[18] were used since the exact hematocrit and plasma
volumes could not be determined after the addition of
urea and sulphuric acid. Then, the discrete ratios were
plotted and obtained a good fit using a one-exponential
curve. It was preferred to use the equation obtained for
blood-to-plasma corrections rather than a constant
value, which would consequently underestimate plasma
concentrations at early time points with perturbation of
tracer uptake or unidirectional influx rate value (i.e. K1)
as a result. In addition, the distribution of the plasma-
to-blood concentration ratio indicates that [18F]FCho, as
[11C]Cho [19], is accumulated into the red blood cells.
Comparing the blood metabolism of [18F]FCho to
[11C]Cho [19], the following accordances were observed:
(1) plasma extraction with chloroform proved that the
amount of lipophilic [18F]FCho metabolites in the
plasma (<5%, Table 1) is negligible, and (2) [18F]FBet was
the only metabolite present in the plasma and it
appeared almost immediately. Indeed, at 5 and 25 min
post injection, 67.47% and 33.43% [18F]FCho could be
detected, which correspond respectively to 62% and 18%
[11C]Cho in the plasma [19] and to the metabolism
pattern as described by Bansal et al. [10]. Therefore, we
can conclude that fitting the percentage of the parent
compound in the plasma to a one-exponential curve
[20] provides a good fit (R2 = 0.9435). When using a
three-exponential function as described by RoivainenFigure 4 Representation of the [18F]FCho influx determined by
the different kinetic models. The tracer influx (Ki) was calculated as
K1*k3/(k2 + k3) for the different tissues.
Figure 5 A Bland-Altman plot representing the intra-observer
variability of the macro-parameters Ki and Patlak's slope. The
test-retest error is plotted as a function of the average [18F]FCho
influx across the cell membranes. Black dots represent data points
from the 3C2i; the black dash-dotted lines represent 95% confidence
interval. The grey dots represent data points from the 2C1i; the grey
lines represent 95% confidence interval. The black crosses represent
data points from the Patlak plot; the black dotted lines represent
95% confidence interval.
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fore, the one-exponential function was applied for
metabolite corrections.
In general, kinetic models are developed as com-
prehensible models, which accurately describe the meta-
bolic process or receptor binding, but are usually
simplified to yield workable models that are able to
quantify a parameter of interest. In oncology, this par-
ameter is usually a specific enzyme or transporter, which
can be described by a micro-parameter of the selected
model. However, in a number of cases, the metabolic
rate, which is a combination of micro-parameters, is
determined, for example, glucose metabolic rate by [18F]
FDG [21] or cell proliferation rate by [18F]FLT [15].
When evaluating the 3C2i model, the [18F]FCho influx
across the cell membranes was calculated with correc-
tions for (possible) [18F]FBet uptake, and the ratio ofFigure 6 A Spearman correlation plot depicting the [18F]FCho influx d[18F]FCho to [18F]FBet uptake in tissues (K1p/K1m) was
determined. The latter designates the magnitude of [18F]
FBet uptake in the tissues and indirectly shows if
additional corrections for [18F]Bet uptake should be
implemented. These experiments showed that despite
the explicit metabolic pattern, [18F]FBet uptake in the
tissues is still limited, and so adjustments for its uptake
should not be accounted for during kinetic modelling.
Indeed, the [18F]FCho influx determined by the 3C2i
model (which corrects for [18F]FBet uptake) and the
sum of the [18F]FCho and [18F]FBet influx as determined
by the 2C1i model were regarded as not statistically
different (Figure 4). Furthermore, when comparing
goodness-of-fit factors (i.e. AIC, SC, and MSC), no
statistical enhancement (or superior fitting) could be
detected by one of the models (i.e. 2C1i and 3C2i). It is
worth noting that reducing the number of compart-
ments, or in this case the input functions, consequently
decreased the %COV of the micro-parameter estimates,
resulting in reduced uncertainties. This was also obser-
ved in the intra-observer variability test. Therefore, we
can conclude that the 2C1i is a workable kinetic model
to estimate the [18F]FCho influx without creating add-
itional errors.
Since [18F]FCho is a tracer which is assumed to be
metabolically trapped in cells, including tumour cells
[22], graphical analysis was applied to quantify the [18F]
FCho influx across cell membranes. We evaluated if
selection of the equilibrium time frame had an influence
on the slope of the Patlak model, which is a measure of
the [18F]FCho influx constant (i.e. Ki). The Spearman
correlation plot showed a good agreement for all tissues,
except for kidney tissue. This might be due to the fact
that the kidneys are responsible for tracer elimination,
which affects the tracer accumulation and therefore
might influence the fitting of the model. Since other
tissues provided good correlations, we might concludeetermined under equilibrium and non-equilibrium conditions.
Figure 7 A visualization of the Patlak model under equilibrium conditions. The equilibrium conditions were obtained by selecting data
points to obtain a linear regression. The grey and green squares represent the individual data points. The green squares are incorporated in the
fitting under equilibrium conditions, whereas non-equilibrium fitting was performed on all the data points (i.e. grey and green data points). The
fitting is represented by the blue line.
Slaets and De Vos EJNMMI Research 2013, 3:66 Page 8 of 9
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linear fitting for this radiotracer. These findings corro-
borate the Spearman correlation test which demonstrates
the insensitivity of the [18F]FCho influx constant (i.e. Ki)
toward the selection of the linear portion. The fitting can
thus be performed without selection of the equilibrium
conditions which considerably simplifies the modelling
process. Hence, graphical analysis, by means of the Patlak
plot, is a very suitable way to estimate [18F]FCho influx
across the cell membranes, except for kidney tissues. It is
worth noting that the influx constant depends on imaging
time, the type of tissue, and the type of tracer used, so pre-
ceding validation studies should be performed prior to im-
plementation of the non-equilibrium data to the fitting
process.
When comparing the [18F]FCho influx calculated by
the 2C1i model (Ki) with the Patlak slope, no statistical
differences were observed (Kruskal-Wallis test), indi-
cating a good agreement between both methods. On the
other hand, the intra-observer variability test (Figure 5)
favours the Patlak model, seeing that this analysis
obtained the smallest percent error. The latter cor-
responds to the highest robust method for absolute
quantification.Conclusions
Despite the early presence of the metabolite [18F]FBet in
the blood, no explicit metabolite uptake was observed in
the tissues. Consequently, modelling of the [18F]FBet
uptake should not be performed during quantification of
[18F]FCho uptake in tissues. [18F]FCho uptake is well
described by the 2C1i and the Patlak model. Our prefer-
ence goes to the latter since it is a reliable, precise, and
robust method independent of scan time or plasma
clearance. In addition, the Patlak plot could easily be
implemented, even under non-equilibrium conditions
and without creating additional errors, for the quantifi-
cation of [18F]FCho uptake as, for example, in a therapy
response assessment.
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